Alkermes Released Topline Results From Vibrance-1 Phase 2 Study Of Alixorexton For Narcolepsy Type 1, Meeting The Primary Endpoint Across All Doses Tested

-2.30%

Alkermes Plc

ALKS

28.50

-2.30%

Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1.
Alixorexton Demonstrated Robust and Consistent Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition at All Doses Tested.
Alixorexton Was Generally Well Tolerated at All Doses Tested.
Detailed Results to Be Presented at Upcoming World Sleep Congress.
Data Support Advancement of Alixorexton to Phase 3 Development in Narcolepsy

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.